bmrn.comBioMarin Pharmaceutical Inc.

Skip to main navigation Skip to main content Skip to Footer Clinical Trials Contact Us Careers -- Home Our Motivation Patient Stories Bailey Kendra Sheri Matty Diseases & Conditions PKU CLN2 Disease MPS VI MPS IVA MPS I Patient & Community Support RARE Scholars In the Hemophilia Community Patient Advocacy BioMarin RareConnections™ Grants & Donations Resource Library Patient Organizations Professional Organizations Our Treatments Our Products PALYNZIQ ® (pegvaliase-pqpz) Injection for PKU Brineura ® (cerliponase alfa) for CLN2 Disease Vimizim ® (elosulfase alfa) for Morquio A Syndrome (MPS IVA) Kuvan ® (sapropterin dihydrochloride) for PKU Aldurazyme ® (laronidase) for MPS I Naglazyme ® (galsulfase) for MPS VI Our Pipeline Valoctocogene Roxaparvovec for Severe Hemophilia A Vosoritide for Achondroplasia BMN 307 for Phenylketonuria (PKU) BMN 331 for Hereditary Angioedema (HAE) Our Company About Us Our History Manufacturing Excellence Message from Chairman and CEO Diversity & Inclusion Global Compliance & Ethics Corporate Social Responsibility Leadership Team Jean-Jacques Bienaimé Henry J. Fuchs, M.D. Jeff Ajer G. Eric Davis C. Greg Guyer, Ph.D. Brian R. Mueller Lon Cardon, Ph.D. Philip Lo Scalzo Amy Wireman Brinda Balakrishnan, M.D., Ph.D. Robert A. Baffi, Ph.D. Board of Directors Funding & Support Grants & Donations Publication Data Request Independent Medical Education Independent Research Investors & Media Press Releases Events & Presentations Corporate Governance Financial Information Analyst Coverage Stock Information Investor FAQs Contact Us Email Alerts Search our website Close Our Motivation Patient Stories Diseases & Conditions Patient & Community Support RARE Scholars In the Hemophilia Community Patient Advocacy BioMarin RareConnections™ Grants & Donations Resources Patient Organizations Professional Organizations Our Treatments Our Products PALYNZIQ® (pegvaliase-pqpz) Injection for PKU Kuvan® (sapropterin dihydrochloride) for PKU Brineura® (cerliponase alfa) for CLN2 Disease ALDURAZYME® (laronidase) for MPS I Vimizim® (elosulfase alfa) for Morquio A Syndrome (MPS IVA) Naglazyme® (galsulfase) for MPS VI Our Pipeline BMN 307 for Phenylketonuria (PKU) BMN 331 for Hereditary Angioedema (HAE) Valoctocogene Roxaparvovec for Severe Hemophilia A Vosoritide for Achondroplasia Compassionate Use Policy Our Company About Us Corporate Social Responsibility Leadership Team Board of Directors Funding & Support Investors & Media Press Releases Events & Presentations Corporate Governance Financial Information Analyst Coverage Stock Information Investor FAQs Contact Us Email Alerts Privacy Policy Terms of Use Site Map Supplier Information LinkedIn Facebook Instagram YouTube Glossary © 2021 BioMarin. All rights reserved. We are honored to be named a 2021 “Best Place to Work for LGBTQ Equality” Learn More ⌃ CAREERS AT BIOMARIN Our focus on rare disease gives us the rare opportunity to truly impact lives. Learn More about careers with BioMarin ⌃ OUR MOTIVATION We are inspired and driven everyday by stories like Sheri’s. Learn More about Sheri ⌃ Patient & Community Support Treatment is only the beginning. We are committed to the communities we treat beyond the therapies we develop. Learn More about our patient support ⌃ OUR PIPELINE We take on the biggest challenges in rare disease. Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address. View Now ⌃ News View All News and press releases ⌃ January 28, 2021 BioMarin Earns Top Marks in Human Rights Campaign’s 2021 Corporate Equality Index January 26, 2021 BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET January 10, 2021 BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set January 5, 2021 BioMarin to Participate in Two Upcoming Virtual Investor Conferences December 21, 2020 BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study December 1, 2020 BioMarin to Participate in Two Upcoming Virtual Investor Conferences November 17, 2020 BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence November 12, 2020 BioMarin to Participate in Three Upcoming Virtual Investor Conferences Home Navigate Our Motivation Our Treatments Our Company Investors & Media About Our History Our Products Our Pipeline Leadership Team Board of Directors Diversity & Inclusion Contact Global Contact Information Our Locations Report a Product Complaint Report Adverse Event Publication Data Request Funding & Support Connect Careers LinkedIn Facebook Instagram YouTube © 2021 BioMarin. All rights reserved. Privacy Policy Terms of Use Supplier Information Site Map Slavery Act Statement Glossary Contact Us This website uses cookies to improve website functionality. You may delete or block cookies by accessing your preferences. For more information, please see our Privacy Policy and Terms and Conditions . By using this website, you consent to our use of cookies. Accept...